Canaccord Genuity Group Issues Positive Forecast for Biogen (NASDAQ:BIIB) Stock Price

Biogen (NASDAQ:BIIB) had its target price boosted by Canaccord Genuity Group from $230.00 to $245.00 in a research note released on Wednesday morning, Marketbeat Ratings reports. The brokerage currently has a buy rating on the biotechnology company’s stock.

A number of other brokerages have also recently commented on BIIB. Wedbush raised their target price on Biogen from $178.00 to $187.00 and gave the stock a “neutral” rating in a report on Monday, February 9th. HC Wainwright boosted their price target on Biogen from $194.00 to $228.00 and gave the company a “buy” rating in a report on Monday, February 9th. Royal Bank Of Canada upped their price target on Biogen from $217.00 to $233.00 and gave the stock an “outperform” rating in a research report on Monday, February 9th. Tudor Pickering set a $201.00 price objective on Biogen in a research note on Monday, February 9th. Finally, TD Cowen lifted their price objective on Biogen from $175.00 to $215.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Twelve analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Biogen currently has an average rating of “Hold” and a consensus price target of $207.96.

Biogen Stock Performance

Shares of NASDAQ BIIB opened at $183.78 on Wednesday. Biogen has a 12-month low of $110.04 and a 12-month high of $202.41. The firm has a market capitalization of $26.97 billion, a price-to-earnings ratio of 20.86, a price-to-earnings-growth ratio of 1.46 and a beta of 0.16. The company has a current ratio of 2.68, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34. The firm has a 50 day moving average of $186.41 and a 200 day moving average of $171.07.

Biogen (NASDAQ:BIIB) last released its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, topping the consensus estimate of $1.61 by $0.38. The business had revenue of $2.28 billion for the quarter, compared to the consensus estimate of $2.21 billion. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The company’s quarterly revenue was down 7.2% on a year-over-year basis. During the same period last year, the firm earned $3.44 earnings per share. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, research analysts anticipate that Biogen will post 15.83 earnings per share for the current year.

Insider Buying and Selling at Biogen

In related news, insider Priya Singhal sold 2,660 shares of the company’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $199.83, for a total value of $531,547.80. Following the completion of the transaction, the insider owned 8,043 shares of the company’s stock, valued at approximately $1,607,232.69. This represents a 24.85% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.18% of the company’s stock.

Hedge Funds Weigh In On Biogen

Several large investors have recently made changes to their positions in BIIB. Reflection Asset Management bought a new stake in Biogen during the 4th quarter valued at approximately $25,000. WPG Advisers LLC lifted its holdings in Biogen by 417.9% in the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 117 shares in the last quarter. First Horizon Corp bought a new position in Biogen in the 4th quarter worth approximately $30,000. Root Financial Partners LLC grew its holdings in Biogen by 198.4% during the 4th quarter. Root Financial Partners LLC now owns 185 shares of the biotechnology company’s stock valued at $33,000 after buying an additional 123 shares in the last quarter. Finally, MV Capital Management Inc. purchased a new stake in Biogen during the 4th quarter valued at approximately $34,000. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Key Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen agreed to acquire Apellis for about $5.6 billion in cash, bringing two commercial immunology/rare‑disease drugs (SYFOVRE®, EMPAVELI®) and a nephrology launch capability — expected to boost near‑term revenue and diversify Biogen beyond MS. Biogen to buy Apellis Pharmaceuticals for $5.6 billion (Reuters)
• Positive Sentiment: Analysts reacted with higher price targets and constructive coverage: Oppenheimer raised its PT to $275 (outperform) and Canaccord to $245 (buy), lifting sentiment that the deal and other pipeline wins improve Biogen’s growth profile. Oppenheimer raises Biogen price target (MarketScreener)
• Positive Sentiment: FDA approval of a higher‑dose SPINRAZA regimen supports Biogen’s rare‑disease revenues and reduces competitive risk in SMA, adding another near‑term commercial tailwind alongside Apellis assets. Biogen secures FDA nod for higher‑dose SPINRAZA (Zacks)
• Neutral Sentiment: Biogen management says combined cash flow from Biogen + Apellis should improve leverage ratios and free capacity for further deals — management framing the purchase as strategic rather than one‑off. Biogen CFO comments on cash flow and M&A capacity (BioPharmaDive)
• Neutral Sentiment: Apellis shares surged (more than doubled) on the takeover premium; that rally reflects deal certainty for Apellis but only partially signals upside for Biogen beyond the strategic rationale. Apellis hits multi‑year high on Biogen deal (Yahoo Finance)
• Negative Sentiment: An investor law firm has opened an investigation into the adequacy of the Apellis sale price/process, which could signal proxy litigation or shareholder pushback that complicates or delays closing. Investor investigation into Apellis sale process (BusinessWire)
• Negative Sentiment: Some analysts remain cautious (Hold ratings cited), pointing to execution risk on Leqembi/ MS erosion, integration risk and the cash outflow’s near‑term impact — these concerns help explain any initial pressure on Biogen shares after the deal news. Analyst caution/hold ratings despite positives (TipRanks)

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.